BCL2 and melanoma: Under certain clinical conditions, RT should be considered as treatment for melanoma.37 HT as an adjuvant has been clinically proven to improve local control of malignant melanoma.38 Its chemoresistance can be overcome in a tumor cell-selective manner by interfering with anti-apoptotic Bcl-2 family members.39, 40 Modulation of apoptotic cell death is therefore a promising strategy to combat cancer and inflammatory diseases in general.